Stock GMDA GAMIDA CELL LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Gamida Cell Ltd.

Equities

GMDA

IL0011552663

Market Closed - OTC Markets
Other stock markets
 20:25:05 03/05/2024 BST 		5-day change 1st Jan Change
0.0145 USD -3.65% Intraday chart for Gamida Cell Ltd. -21.20% -96.49%
04-10 Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index CI
04-05 Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index CI

Evolution of the average Target Price on Gamida Cell Ltd.

Price target over the last 5 years

History of analyst recommendation changes

5438abf7416b9ffa2dba13.FeCAbdSUaATj2tJU7VjoqW6oCfNU6QhakJ65lyVUWP8.doXIJITRXV2Kub4LpRe8wCr-WrUum2I-pdT-3x0iH7NW0-gn-fMlRpCblw~af864903b242bc9f272180c5e35bcba2

Analyst Recommendations on Gamida Cell Ltd.

JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform MT
Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating MT
JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating MT
Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating MT
Needham Lowers Price Target on Gamida Cell to $6 From $8, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Gamida Cell to $11 From $5, Keeps Buy Rating MT
Oppenheimer Adjusts Gamida Cell Price Target to $8 From $10, Maintains Outperform Rating MT
HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $22, Maintains Buy Rating MT
Needham Adjusts Price Target on Gamida Cell to $8 From $9, Maintains Buy Rating MT
Oppenheimer Adjusts Gamida Cell PT to $10 From $15, Notes Uncertainty Around Ex-US Regulatory, Commercial Strategy; Maintains Outperform Rating MT
Piper Sandler Adjusts Gamida Cell's Price Target to $7 From $8, Reiterates Overweight Rating MT
Needham Adjusts Price Target on Gamida Cell to $12 from $14, Keeps Buy Rating MT
Oppenheimer Adjusts Gamida Cell PT to $15 From $17, Maintains Outperform Rating MT
RBC Cuts Price Target on Gamida Cell to $11 From $14, Citing Setback to Omidubicel Filing Timeline; Outperform-Speculative Risk Rating Kept MT
GAMIDA CELL : RBC Capital Adjusts Gamida Cell PT to $14 From $12, Maintains Outperform - Speculative Risk MT
GAMIDA CELL : Needham Adjusts Price Target on Gamida Cell to $14 From $17, Maintains Buy Rating MT
GAMIDA CELL : Oppenheimer Adjusts Gamida Cell PT to $17 From $20, Maintains Outperform Rating MT
GAMIDA CELL : RBC Capital Adjusts Gamida Cell's Price Target to $12 From $13, Maintains Outperform-Speculative Risk Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.0145 USD
Average target price
6 USD
Spread / Average Target
+41,279.31%
High Price Target
6 USD
Spread / Highest target
+41,279.31%
Low Price Target
6 USD
Spread / Lowest Target
+41,279.31%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Gamida Cell Ltd.

JMP Securities
Piper Sandler
HC Wainwright
Oppenheimer
Needham & Co.
RBC Capital Markets

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GMDA Stock
  4. Consensus Gamida Cell Ltd.